24 February 2011
Melbourne diagnostic technology company HealthLinx Limited (ASX: HTX) has achieved a critical milestone with notification that the UK patent office has granted a patent for its OvPlex™ product.
This is the first jurisdiction to complete a review of the patent for the company’s lead product, the ovarian cancer diagnostic technology known as the OvPlex™ Panel.
It has deemed all claims as novel, inventive and to have industrial application.
HealthLinx managing director Mr Nick Gatsios said the UK patent represents an important validation of the OvPlex™ panel’s first in class technology.
“This is a major milestone for the company to have our core patent granted in a major jurisdiction such as the UK,” he said.
The OvPlex™ test examines a series of biomarkers from a blood sample deemed important in the diagnosis of ovarian cancer. It includes the current ‘gold standard’ biomarker CA125. Importantly, the granted patent covers not only the combination of proprietary biomarkers, but also the methodology used for implementing the test in a typical clinical pathology environment.
A recent release of clinical data highlighted that initial analysis of its multi-national ovarian cancer biomarker study confirmed the superior diagnostic performance of the OvPlex™ technology compared with CA125 alone.
Mr Gatsios said the company had filed to patent its OvPlex™ technology in all major jurisdictions and was now awaiting final reviews.